M-LIFE™ Multitargeting Cancer Drug Prospect MLS-222QLD Successfully Advancing Through Pre-Clinical Testing

by Rachel Albertson | Mar 10, 2022 | Contact

M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing.   This molecule is one of several...

iCFO Capital recently partnered with Moskal Lifesciences to raise $3.5M seed funding

by Rachel Albertson | Dec 18, 2021 | Contact

SAN DIEGO, CALIFORNIA, DECEMBER, 2021 – iCFO Capital recently partnered with Moskal Lifesciences, LLC to raise $3.5M seed funding for expand growth from iCFO Capital investor network in San Diego, California. Moskal Lifesciences, LLC uses Novel Algorithms to...

M-Life™ Novel IL-6 Molecules and Efficacy/Toxicity Data

by Rachel Albertson | Nov 20, 2020 | Contact

https://www.biospace.com/article/m-life-reveals-il-6-efficacy-toxicity-trade-offs-for-novel-botanical-based-analog-molecules-/

M-Life™ COVID-19 Cytokine Storm Repurposing Possibilities

by Rachel Albertson | Oct 9, 2020 | Contact

https://www.biospace.com/article/m-life-adds-cytokine-storm-acting-drugs-to-its-list-of-prospective-repurposed-covid-19-drugs-/

M-Life™ Toxicity Predictions for Repurposed COVID-19 Drugs

by Rachel Albertson | Sep 11, 2020 | Contact

https://www.biospace.com/article/m-life-releases-toxicity-predictions-for-covid-19-drugs/

M-Life™ Drugs on Market as Repurposing Prospects for the Treatment of COVID-19

by Rachel Albertson | Aug 15, 2020 | Contact

https://www.biospace.com/article/using-new-computational-methods-m-life-identifies-additional-on-market-drugs-for-repurpose-to-treat-covid-19-/